ATE288757T1 - Ppar-alpha und ppar-gamma-hemmer - Google Patents
Ppar-alpha und ppar-gamma-hemmerInfo
- Publication number
- ATE288757T1 ATE288757T1 AT99944810T AT99944810T ATE288757T1 AT E288757 T1 ATE288757 T1 AT E288757T1 AT 99944810 T AT99944810 T AT 99944810T AT 99944810 T AT99944810 T AT 99944810T AT E288757 T1 ATE288757 T1 AT E288757T1
- Authority
- AT
- Austria
- Prior art keywords
- ppar
- alpha
- medicinal drug
- gamma
- fatty acid
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 102000000536 PPAR gamma Human genes 0.000 abstract 2
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 150000007970 thio esters Chemical class 0.000 abstract 2
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 108010028924 PPAR alpha Proteins 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1999/005217 WO2001021181A1 (en) | 1999-09-24 | 1999-09-24 | PPARα AND PPARη INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE288757T1 true ATE288757T1 (de) | 2005-02-15 |
Family
ID=14236796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99944810T ATE288757T1 (de) | 1999-09-24 | 1999-09-24 | Ppar-alpha und ppar-gamma-hemmer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6762171B1 (de) |
| EP (1) | EP1214939B1 (de) |
| AT (1) | ATE288757T1 (de) |
| AU (1) | AU5759499A (de) |
| CA (1) | CA2383140C (de) |
| DE (1) | DE69923718T2 (de) |
| WO (1) | WO2001021181A1 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1220669A4 (de) * | 1999-10-13 | 2004-12-08 | Marco A Chacon | THERAPEUTISCHE MASSNAHME, UM DEN EFFEKT EINER KALORIENBESCHRäNKUNG NACHZUAHMEN |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| JP4711600B2 (ja) | 2001-01-26 | 2011-06-29 | シェーリング コーポレイション | シトステロール血症の処置のための置換アゼチジノン化合物の使用 |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| AU4755502A (en) * | 2001-06-14 | 2002-12-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Cofactor-based screening method for nuclear receptor modulators and related modulators |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| CA2576993C (en) * | 2004-08-12 | 2013-09-24 | Amgen Inc. | Bisaryl-sulfonamides |
| EP2079476B1 (de) * | 2006-10-20 | 2014-05-21 | Dow Global Technologies LLC | Verwendung hydroxypropylmethylcellulose zur vorbeugung oder behandlung des stoffwechselsyndroms |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9670153B2 (en) * | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0482097T3 (da) | 1989-07-11 | 2001-09-17 | Genentech Inc | Tensidpræparater og fremgangsmåder |
| AU7074496A (en) | 1995-09-18 | 1997-04-09 | Ligand Pharmaceuticals Incorporated | Ppar gamma antagonists for treating obesity |
| WO1998051296A1 (en) * | 1997-05-15 | 1998-11-19 | Schmidt Geoffrey J | Method of reducing immunological tolerance to malignancy |
-
1999
- 1999-09-24 CA CA002383140A patent/CA2383140C/en not_active Expired - Fee Related
- 1999-09-24 DE DE69923718T patent/DE69923718T2/de not_active Expired - Lifetime
- 1999-09-24 AU AU57594/99A patent/AU5759499A/en not_active Abandoned
- 1999-09-24 WO PCT/JP1999/005217 patent/WO2001021181A1/ja not_active Ceased
- 1999-09-24 US US10/070,439 patent/US6762171B1/en not_active Expired - Fee Related
- 1999-09-24 EP EP99944810A patent/EP1214939B1/de not_active Expired - Lifetime
- 1999-09-24 AT AT99944810T patent/ATE288757T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1214939A4 (de) | 2003-10-01 |
| EP1214939A1 (de) | 2002-06-19 |
| DE69923718T2 (de) | 2006-01-12 |
| DE69923718D1 (de) | 2005-03-17 |
| WO2001021181A1 (en) | 2001-03-29 |
| AU5759499A (en) | 2001-04-24 |
| EP1214939B1 (de) | 2005-02-09 |
| CA2383140A1 (en) | 2001-03-29 |
| CA2383140C (en) | 2007-12-04 |
| US6762171B1 (en) | 2004-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE288757T1 (de) | Ppar-alpha und ppar-gamma-hemmer | |
| CY1108823T1 (el) | Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3 | |
| RU2325389C2 (ru) | Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью | |
| AR033796A1 (es) | Composicion farmaceutica | |
| ATE182581T1 (de) | Metalloproteinase-inhibitoren | |
| BRPI0409037A (pt) | fungicidas que contém composto metil éster de ácido metóxi acrìlico | |
| UA26455C2 (uk) | Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта | |
| DOP2008000001A (es) | Oxazolidinonas substituidas y su uso | |
| MA31432B1 (fr) | Metabolites de derives de (thio) carbamoyl-cyclohexane | |
| CY1110906T1 (el) | Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης | |
| ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| EP0253327A3 (en) | Diphenylpropylamine derivatives, their manufacture and tdiphenylpropylamine derivatives, their manufacture and their pharmaceutical application heir pharmaceutical application | |
| CY1116274T1 (el) | Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας | |
| PT1150686E (pt) | Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina | |
| GB2460784A (en) | Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition | |
| LV10267A (lv) | Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai | |
| AR035006A1 (es) | Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento. | |
| NO940274L (no) | 2-(4-(4-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler | |
| BRPI0607214B8 (pt) | derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação | |
| FR2387221A1 (fr) | Derives du benzimidazole utilisables comme substances actives de medicaments veterinaires | |
| BR0015423A (pt) | Análogos de ácido 15-hidroxieicosatetraenóico interrompidos por heteroátomo e métodos de uso | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
| ATE286395T1 (de) | Antithrombotische mittel | |
| FR2376661A1 (fr) | Medicaments anthelminthiques renfermant comme substances actives des anilinomethylene-malononitriles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |